Acting US FDA chief meets with rare disease groups to mend fences
Brief: Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
Brief: Biohaven Files For Offering Of Up To $350 Million Common Shares - SEC Filing
Brief: Biohaven Ltd Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Rivian, Biohaven, CervoMed
Biohaven rises after completing enrollment in mid-stage obesity drug trial
Brief: Biohaven's Phase 2 Obesity Study With Taldefgrobep Alfa, A Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
U.S. RESEARCH ROUNDUP- Biogen, Eli Lilly, Johnson & Johnson
Biohaven Q4 net loss narrows
U.S. STOCKS ON THE MOVE-Target, natgas firms, copper miners
U.S. STOCKS ON THE MOVE-Target, natgas firms, copper miners
Biohaven falls after depression drug fails mid-stage trial
U.S. STOCKS ON THE MOVE-Adicet Bio, Coupang, Biohaven,
U.S. STOCKS ON THE MOVE-Biohaven, silver miners, gold miners
Biohaven falls after depression drug fails mid-stage trial
Biohaven's depression drug fails mid-stage trial, shares fall
Biohaven falls after depression drug fails mid-stage trial